选择性D-1多巴胺受体激动剂和拮抗剂在精神病学和神经病学中的治疗潜力。 - Suppr

Suppr

超能文献

Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology.

作者信息

Waddington J L

机构信息

Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin.

出版信息

Gen Pharmacol. 1988;19(1):55-60. doi: 10.1016/0306-3623(88)90005-5.

DOI:10.1016/0306-3623(88)90005-5

PMID:3278946

Abstract

摘要

相似文献

Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology.选择性D-1多巴胺受体激动剂和拮抗剂在精神病学和神经病学中的治疗潜力。

Gen Pharmacol. 1988;19(1):55-60. doi: 10.1016/0306-3623(88)90005-5.

Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.《多巴胺受体亚型选择性药物的研发进展：神经和精神疾病的潜在治疗方法》更新1

Chem Rev. 2013 May 8;113(5):PR123-78. doi: 10.1021/cr300113a. Epub 2013 Mar 7.

Beta-adrenoceptor antagonists in psychiatry and neurology.

Pharmacol Ther. 1981;12(2):419-37. doi: 10.1016/0163-7258(81)90089-9.

[Increased knowledge of dopamine receptors results in better drugs in the treatment of neurologic and psychological disorders].对多巴胺受体认识的增加带来了治疗神经和心理疾病的更好药物。

Lakartidningen. 1991 Aug 28;88(35):2761-5.

Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.多巴胺受体亚型选择性药物研发的最新进展：用于神经和精神疾病的潜在疗法

Chem Rev. 2007 Jan;107(1):274-302. doi: 10.1021/cr050263h.

Use of beta-blocking drugs in psychiatry and neurology.β受体阻滞剂在精神病学和神经病学中的应用。

Drugs. 1980 Oct;20(4):300-8. doi: 10.2165/00003495-198020040-00004.

Dopamine receptors and antipsychotic drug response.多巴胺受体与抗精神病药物反应

Br J Psychiatry Suppl. 1993 Dec(22):31-8.

D-3 receptor agonists: combined action neurologic and neuropsychiatric agents.D-3受体激动剂：神经和神经精神药物的联合作用

J Neurol Sci. 1999 Feb 1;163(1):2-3. doi: 10.1016/s0022-510x(98)00306-2.

[Use of peptides in psychiatry and neurology (review)].

Zh Nevropatol Psikhiatr Im S S Korsakova. 1987;87(8):1244-8.

[The chronobiological approach--a way to enhance the efficacy of pharmacotherapy in neurology and psychiatry].

Eksp Klin Farmakol. 1992 Jul-Aug;55(4):67-9.

引用本文的文献

Virtual Compound Screening for Discovery of Dopamine D1 Receptor Biased Allosteric Modulators.用于发现多巴胺D1受体偏向性变构调节剂的虚拟化合物筛选

J Chem Inf Model. 2025 Sep 22;65(18):9713-9722. doi: 10.1021/acs.jcim.5c00972. Epub 2025 Sep 11.

PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.PF-06649751治疗早期帕金森病的疗效与安全性：一项随机、安慰剂对照试验

Ther Adv Neurol Disord. 2020 Mar 6;13:1756286420911296. doi: 10.1177/1756286420911296. eCollection 2020.

Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated.1期帕金森病研究表明，多巴胺D1/D5激动剂PF-06649751安全且耐受性良好。

Neurol Ther. 2018 Dec;7(2):307-319. doi: 10.1007/s40120-018-0114-z. Epub 2018 Oct 25.

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor.D1多巴胺受体的非儿茶酚胺激动剂导致β-抑制蛋白募集受损和脱敏作用减弱。

Nat Commun. 2018 Feb 14;9(1):674. doi: 10.1038/s41467-017-02776-7.

Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.非典型抗精神病药物的作用机制与精神分裂症的神经生物学

CNS Drugs. 2006;20(5):389-409. doi: 10.2165/00023210-200620050-00004.

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.理解抗精神病药物的“非典型性”：一个临床和药理学上不断变化的目标。

J Psychiatry Neurosci. 2003 Jul;28(4):275-84.

SCH 23390: the first selective dopamine D1-like receptor antagonist.SCH 23390：首个选择性多巴胺D1样受体拮抗剂。

CNS Drug Rev. 2001 Winter;7(4):399-414. doi: 10.1111/j.1527-3458.2001.tb00207.x.

Affinity of neuroleptics for D1 receptor of human brain striatum.抗精神病药物对人脑纹状体D1受体的亲和力。

J Psychiatry Neurosci. 1994 Jul;19(4):265-9.

Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.对先前停用氟哌啶醇治疗的卷尾猴长期给予 D1 受体拮抗剂 SCH 23390 和 D2 受体拮抗剂雷氯必利治疗。锥体外系综合征和多巴胺能超敏反应。

Psychopharmacology (Berl). 1993;112(2-3):389-97. doi: 10.1007/BF02244938.

Further evidence for two directions of D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502.

Psychopharmacology (Berl). 1989;98(2):245-50. doi: 10.1007/BF00444699.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验